NYU Langone Health
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, NYU Langone Health sits in the top decile of US sponsors by registered trial count (#25 of 15,742 sponsors by registered trial count).
NYU Langone Health: 1,164 sponsored US clinical trials, 197 recruiting.
NYU Langone Health sponsors 1,164 registered US clinical trials on ClinicalTrials.gov, 197 of them currently recruiting, and 741 completed. 123 of these trials are in Phase 3-4 (later-stage) and 231 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Prostate Cancer, with 12 trials.
Top-decile sponsor footprint
NYU Langone Health ranks in the top decile of sponsors by registered trial count (#25 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
741 of 866 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (85.6%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
1,164 total, page 19 of 24
Exploring the Activity of RAD001 in Vestibular Schwannomas and Meningiomas
NCT01880749
Platelet Activity in Vascular Surgery for Thrombosis and Bleeding
NCT01897103
Anti-inflammatory Effects of Colchicine in PCI
NCT01709981
Functional Brain Imaging in PTSD
NCT02053532
Concussion and Post Traumatic Stress in Traumatic Brain Injury
NCT02119533
Promoting Safe Use of Pediatric Liquid Medications
NCT01854151
Helping Hypertensive Latinos to Improve Medication Adherence
NCT03560596
Effectiveness Trial for Evaluating IAHA for PFPS
NCT01811654
Tailored Approaches to Improve Medication Adherence
NCT01643473
Dentistry United to Extinguish Tobacco
NCT01615237
Improving Adherence to Smoking Cessation Medication Among PLWHA
NCT01898195
The Effects Of Bronchodilator Therapy On Respiratory And Autonomic Function In Patients With Familial Dysautonomia
NCT01987219
Prospective Study of 2 mm Margins for the Biopsy of Dysplastic Nevi
NCT03094273
Evaluating for Type-2 Diabetes in the Very Early Postpartum Period
NCT01988987
Effects Contrast on Platelet Activity, Thrombosis and Fibrinolysis in Patients Undergoing Coronary Angiography
NCT01848899
Impact of Estrogen on Fear Extinction R61
NCT02673606
Brachial Plexus Block in Post-Op Pain Control After Distal Upper Extremity Fracture: A Prospective Randomized Study
NCT01968824
Randomized, Placebo-Controlled Study: Effects of Lavender Aromatherapy on Preoperative Anxiety in Breast Patients
NCT01837966
Combining Entertainment & Influenza Education for Pediatric Patients
NCT01788514
The Use of Paravertebral Block for Cardiac Surgery
NCT02180893
Evaluation of PET/MR and PET/CT Imaging for Bone Marrow Lesions
NCT01880762
Phase II Randomized Trial of Ipilimumab Versus Ipilimumab and Radiotherapy in Metastatic Melanoma
NCT01689974
Romiplostim in Increasing Low Platelet Counts in Patients With Multiple Myeloma Receiving Chemotherapy
NCT01676961
Water Oxygenation and Brain Activity
NCT02688452
Insulin Resistance and Cognitive Dysfunction in Obese Adolescents: Pilot Study
NCT01737658
A Comparison of Ketamine Infusion Versus Placebo in Opioid Tolerant and Opioid Naive Patients After Spinal Fusion
NCT03274453
Symptom Management for Irritable Bowel Syndrome
NCT02079857
Bariatric Lap Band Surgery as a Treatment for Knee Osteoarthritis
NCT02272218
Insights for Community Health
NCT01681862
Cystine Capacity Clinical Study (CysCap)
NCT02120105
The Role of Bacterial Overgrowth and Delayed Intestinal Transit in Hepatic Encephalopathy.
NCT01846806
Tocilizumab for the Treatment of Behcet's Syndrome
NCT01693653
Discharge Educational Strategies for Reduction of Vascular Events
NCT01836354
Left Versus Right Radial Artery and Radiation Exposure in Patients With Predictors of Trans-radial Failure
NCT01707524
Mucosal Immunity of Ulcerative Colitis Patients Undergoing Therapy With Trichuris Suis Ova
NCT01433471
Relationship Between Attention and Emotional Regulation Post-Traumatic Brain Injury (TBI)
NCT01681589
Dexamethasone Versus Ketorolac Injection for the Treatment of Local Inflammatory Hand and Upper Extremity Disorders
NCT02266433
International Study of Comparative Health Effectiveness With Medical and Invasive Approaches (ISCHEMIA)
NCT01471522
Biomarkers in First Episode Schizophrenia
NCT02033382
The Human Epilepsy Project
NCT02126774
Initial Assessment of 18FDG-PET/MRIin Determining the Extent of Systemic Disease in Breast Cancer Patients
NCT01672021
Factors Associated With End Stage Liver Disease
NCT01846819
Use of Multi-Parametric MRI With Prostate Biopsy for Cancer Diagnosis.
NCT01964638
Prevention Trial to Achieve Cardiovascular Targets
NCT01642355
Effect of Increasing Doses of Cystine Binding Thiol Drugs on Cystine Capacity in Patients With Cystinuria
NCT02125721
A Pilot Study of the Safety and Efficacy of Abatacept Injections in the Treatment of Behcet's Syndrome
NCT01693640
CB1 Receptor PET Imaging Reveals Gender Differences in PTSD
NCT02237677
STAT3 in T Cells: At The Crossroads of Inflammation and Cancer
NCT01663571
Evaluation of Salt Sensitivity in Young Adults
NCT02588352
Pharmacokinetic Study of Pitavastatin and Ritonavir-Boosted Darunavir or Efavirenz
NCT01695954
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 99 |
| Phase 2 | 132 |
| Phase 3 | 28 |
| Phase 4 | 95 |
Therapeutic Areas
What is open in the NYU Langone Health pipeline
197 recruiting of 1,164 indexed (17% open); 741 completed (64%).
Phase mix: 123 late (III/IV) vs 231 early (I/II) (early-phase heavy).
Top condition: Prostate Cancer (12 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
NYU Langone Health: open-pipeline peers nationwide
Peers matched on 1,164 registered trials and 17% open enrollment, not the therapeutic-area sidebar.
NYU Langone Health sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 1,164 trials (± recruiting share)
- University of Alabama at Birmingham · 1,160 trials · 19% recruiting
- Wake Forest University Health Sciences · 1,140 trials · 15% recruiting
- Emory University · 1,208 trials · 17% recruiting
- Northwestern University · 1,209 trials · 15% recruiting
Sponsors near 17% open enrollment (± trial volume)
- CSL Behring · 17% recruiting · 71 trials
- Penn State University · 17% recruiting · 219 trials
- University of Hawaii · 17% recruiting · 77 trials
- University of Utah · 17% recruiting · 818 trials
Related
What to do with this NYU Langone Health page
1,164 registered trials is a research-attention snapshot, not an endorsement of NYU Langone Health or any single study.
- 197 of NYU Langone Health's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Prostate Cancer is the condition NYU Langone Health studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Prostate Cancer trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
NYU Langone Health pipeline card: 1,164 registered trials from official public datasets.Report a data error.